{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:54Z","timestamp":1792552314115,"version":"4.5.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI43957"],"award-info":[{"award-number":["AI43957"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Bruton\u2019s tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-cell survival and proliferation. Designing new inhibitors of BTK has been an important objective for advancing development of improved therapeutic agents against cancer and autoimmune disorders. Based on the success of Ibrutinib, several second-generation irreversible BTK inhibitors have been developed that exhibit fewer off-target effects. However, the binding-mode and their interaction with Btk have not been experimentally determined and evaluated at atomic resolution. Here we determined the first crystal structure of the BTK kinase domain in complex with acalabrutinib. In addition, we report a structure of the BTK\/tirabrutinib complex and compare these structures with previously solved structures. The structures provide insight in the superior selectivity reported for acalabrutinb and guide future BTK inhibitor development.<\/jats:p>","DOI":"10.1371\/journal.pone.0290872","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T13:28:13Z","timestamp":1693488493000},"page":"e0290872","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6149-5236","authenticated-orcid":true,"given":"David Y.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-7244","authenticated-orcid":true,"given":"Amy H.","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"3","key":"pone.0290872.ref001","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0952-7915(00)00088-1","article-title":"Tec family kinases in lymphocyte signaling and function","volume":"12","author":"EM Schaeffer","year":"2000","journal-title":"Curr Opin Immunol"},{"issue":"6409","key":"pone.0290872.ref002","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"D Vetrie","year":"1993","journal-title":"Nature"},{"issue":"2","key":"pone.0290872.ref003","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances","volume":"35","author":"T Wen","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"pone.0290872.ref004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13543776.2019.1594777","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010\u20132018).","volume":"29","author":"Y Feng","year":"2019","journal-title":"Expert Opin Ther Pat."},{"key":"pone.0290872.ref005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of Bruton\u2019s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.","volume":"151","author":"C Liang","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"14","key":"pone.0290872.ref006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147641","article-title":"Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.","volume":"22","author":"C Brullo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"pone.0290872.ref007","doi-asserted-by":"crossref","first-page":"113329","DOI":"10.1016\/j.ejmech.2021.113329","article-title":"Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): Current development.","volume":"217","author":"J Liu","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"6","key":"pone.0290872.ref008","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton Tyrosine Kinase Inhibitors: Present and Future.","volume":"25","author":"JA Burger","year":"2019","journal-title":"Cancer J"},{"issue":"16","key":"pone.0290872.ref009","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26164907","article-title":"Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases.","volume":"26","author":"D Zhang","year":"2021","journal-title":"Molecules."},{"issue":"5","key":"pone.0290872.ref010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cpt.85","article-title":"Targeting Bruton\u2019s tyrosine kinase with ibrutinib in B-cell malignancies","volume":"97","author":"Y Wang","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0290872.ref011","doi-asserted-by":"crossref","first-page":"662223","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.","volume":"12","author":"GE Ringheim","year":"2021","journal-title":"Front Immunol."},{"issue":"8","key":"pone.0290872.ref012","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/all.15261","article-title":"Bruton\u2019s tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions","volume":"77","author":"P Mendes-Bastos","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"pone.0290872.ref013","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase.","volume":"2","author":"Z Pan","year":"2007","journal-title":"ChemMedChem."},{"issue":"29","key":"pone.0290872.ref014","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"LA Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"pone.0290872.ref015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"JA Burger","year":"2019","journal-title":"Blood"},{"issue":"4","key":"pone.0290872.ref016","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/ejh.13573","article-title":"Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed\/resistant chronic lymphocytic leukemia cases","volume":"106","author":"F Morabito","year":"2021","journal-title":"Eur J Haematol"},{"issue":"24","key":"pone.0290872.ref017","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"JA Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0290872.ref018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.","volume":"1","author":"KJ Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"pone.0290872.ref019","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.","volume":"29","author":"S Cheng","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"pone.0290872.ref020","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"RR Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0290872.ref021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"TM Liu","year":"2015","journal-title":"Blood"},{"issue":"13","key":"pone.0290872.ref022","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.","volume":"35","author":"JA Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0290872.ref023","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: Beyond Ibrutinib.","volume":"14","author":"DA Bond","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"pone.0290872.ref024","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/CCO.0000000000000897","article-title":"Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia","volume":"34","author":"F Perutelli","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"pone.0290872.ref025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: First Approval","volume":"81","author":"S. Dhillon","year":"2021","journal-title":". Drugs"},{"issue":"8","key":"pone.0290872.ref026","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","article-title":"Tirabrutinib: First Approval","volume":"80","author":"S. Dhillon","year":"2020","journal-title":". Drugs"},{"key":"pone.0290872.ref027","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and selectivity of BTK inhibitors in clinical development for B-Cell malignancies.","volume":"132","author":"A dBG Kaptein","year":"2018","journal-title":"Blood"},{"issue":"13","key":"pone.0290872.ref028","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/14656566.2022.2113384","article-title":"Approved and emerging Bruton\u2019s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia","volume":"23","author":"A Hatashima","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"pone.0290872.ref029","article-title":"The Use of Bruton Tyrosine Kinase Inhibitors in Waldenstrom\u2019s Macroglobulinemia.","volume":"12","author":"AM Khan","year":"2022","journal-title":"J Pers Med."},{"key":"pone.0290872.ref030","doi-asserted-by":"crossref","first-page":"20406207221101697","DOI":"10.1177\/20406207221101697","article-title":"The potential of pirtobrutinib in multiple B-cell malignancies.","volume":"13","author":"JL Jensen","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"pone.0290872.ref031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: First Approval.","volume":"80","author":"YY Syed","year":"2020","journal-title":"Drugs"},{"issue":"17","key":"pone.0290872.ref032","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"62","author":"Y Guo","year":"2019","journal-title":"J Med Chem"},{"issue":"Pt 7","key":"pone.0290872.ref033","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"PR Evans","year":"2013","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 2","key":"pone.0290872.ref034","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"Xds","volume":"66","author":"W. Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 4","key":"pone.0290872.ref035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1107\/S0907444911007773","article-title":"Data processing and analysis with the autoPROC toolbox","volume":"67","author":"C Vonrhein","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 4","key":"pone.0290872.ref036","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"MD Winn","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 4","key":"pone.0290872.ref037","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"AJ McCoy","year":"2007","journal-title":"J Appl Crystallogr"},{"issue":"Pt 4","key":"pone.0290872.ref038","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1107\/S090744491200251X","article-title":"JLigand: a graphical tool for the CCP4 template-restraint library","volume":"68","author":"AA Lebedev","year":"2012","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 10","key":"pone.0290872.ref039","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1107\/S0907444909029436","article-title":"electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation.","volume":"65","author":"NW Moriarty","year":"2009","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 10","key":"pone.0290872.ref040","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix","volume":"75","author":"D Liebschner","year":"2019","journal-title":"Acta Crystallogr D Struct Biol"},{"issue":"Pt 4","key":"pone.0290872.ref041","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"P Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"pone.0290872.ref042","article-title":"The PyMOL Molecular Graphics System DeLano Scientific, San Carlos, CA, USA.","author":"WL DeLano","year":"2002"},{"issue":"290","key":"pone.0290872.ref043","doi-asserted-by":"crossref","first-page":"ra76","DOI":"10.1126\/scisignal.2004298","article-title":"Activation loop dynamics determine the different catalytic efficiencies of B cell- and T cell-specific tec kinases.","volume":"6","author":"RE Joseph","year":"2013","journal-title":"Sci Signal."},{"key":"pone.0290872.ref044","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06074","article-title":"Autoinhibition of Bruton\u2019s tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate.","volume":"4","author":"Q Wang","year":"2015","journal-title":"Elife"},{"issue":"3","key":"pone.0290872.ref045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton\u2019s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling","volume":"91","author":"AT Bender","year":"2017","journal-title":"Mol Pharmacol"},{"key":"pone.0290872.ref046","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60470","article-title":"Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.","volume":"9","author":"RE Joseph","year":"2020","journal-title":"Elife"},{"issue":"2","key":"pone.0290872.ref047","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile","volume":"363","author":"T Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"pone.0290872.ref048","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","article-title":"Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells","volume":"23","author":"V Patel","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"pone.0290872.ref049","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.","volume":"374","author":"JC Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0290872.ref050","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.","volume":"23","author":"SEM Herman","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T13:28:40Z","timestamp":1693488520000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290872"}},"subtitle":[],"editor":[{"given":"Gurudeeban","family":"Selvaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0290872","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}